4//SEC Filing
Pang Phillip 4
Accession 0001209191-23-035409
CIK 0001706431other
Filed
Jun 7, 8:00 PM ET
Accepted
Jun 8, 4:30 PM ET
Size
12.9 KB
Accession
0001209191-23-035409
Insider Transaction Report
Form 4
Pang Phillip
Chief Medical Officer
Transactions
- Sale
Common Stock
2023-06-07$25.95/sh−5,000$129,727→ 188,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-06-07−5,000→ 47,591 totalExercise: $1.53Exp: 2028-04-27→ Common Stock (5,000 underlying) - Exercise/Conversion
Common Stock
2023-06-07$1.53/sh+5,000$7,650→ 193,000 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2023.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.63 to $26.31 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
Documents
Issuer
Vir Biotechnology, Inc.
CIK 0001706431
Entity typeother
Related Parties
1- filerCIK 0001787370
Filing Metadata
- Form type
- 4
- Filed
- Jun 7, 8:00 PM ET
- Accepted
- Jun 8, 4:30 PM ET
- Size
- 12.9 KB